- Home
- ABSI vs EBS Comparison
ABSI vs EBS Comparison
Compare ABSI & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- EBS
- Stock Information
- Founded
- ABSI 2011
- EBS 1998
- Country
- ABSI United States
- EBS United States
- Employees
- ABSI N/A
- EBS 900
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- EBS Health Care
- Exchange
- ABSI Nasdaq
- EBS Nasdaq
- Market Cap
- ABSI 338.0M
- EBS 359.3M
- IPO Year
- ABSI 2021
- EBS 2006
- Fundamental
- Price
- ABSI $2.67
- EBS $7.30
- Analyst Decision
- ABSI Strong Buy
- EBS Strong Buy
- Analyst Count
- ABSI 4
- EBS 3
- Target Price
- ABSI $8.75
- EBS $14.33
- AVG Volume (30 Days)
- ABSI 4.1M
- EBS 1.4M
- Earning Date
- ABSI 08-13-2025
- EBS 08-05-2025
- Dividend Yield
- ABSI N/A
- EBS N/A
- EPS Growth
- ABSI N/A
- EBS N/A
- EPS
- ABSI N/A
- EBS N/A
- Revenue
- ABSI $4,815,000.00
- EBS $965,400,000.00
- Revenue This Year
- ABSI $81.76
- EBS N/A
- Revenue Next Year
- ABSI $287.79
- EBS $18.88
- P/E Ratio
- ABSI N/A
- EBS N/A
- Revenue Growth
- ABSI N/A
- EBS N/A
- 52 Week Low
- ABSI $2.01
- EBS $4.02
- 52 Week High
- ABSI $6.33
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- ABSI 46.51
- EBS 62.33
- Support Level
- ABSI $2.54
- EBS $6.59
- Resistance Level
- ABSI $2.92
- EBS $7.29
- Average True Range (ATR)
- ABSI 0.15
- EBS 0.39
- MACD
- ABSI 0.01
- EBS 0.05
- Stochastic Oscillator
- ABSI 41.86
- EBS 92.89
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.